Neuronal membrane fluidity modulation

Neuronal membrane fluidity modulation refers to the process by which the physical state—specifically, the viscosity or "fluidity"—of neuronal plasma membranes is altered through changes in lipid composition. This property is primarily determined by the relative concentrations of cholesterol, saturated/unsaturated fatty acids, and specific phospholipids such as phosphatidylethanolamine and phosphatidylserine. Increased cholesterol content generally decreases membrane fluidity, leading to more rigid domains that can affect protein localization and function; conversely, higher levels of unsaturated fatty acids or certain phospholipids increase fluidity. These changes influence critical neuronal processes including vesicle trafficking, synaptic transmission, receptor clustering/distribution, susceptibility to neurotoxic peptides like amyloid-beta (Aβ), and overall cellular signaling. While not a single molecular target but rather a biophysical property modulated by various molecules or drugs (such as azelaic acid derivatives), intentional alteration of neuronal membrane fluidity has been proposed as a novel therapeutic strategy for diseases involving disrupted cell signaling or neurotoxicity. However, "neuronal membrane fluidity modulation" itself is not a discrete receptor/protein/enzyme but describes an emergent property influenced by many molecular components.

Other names

Membrane fluidity modulationPlasma membrane fluidity regulationAdaptive membrane fluidity modulation (AMFM)

Alteration of plasma membrane lipid composition to change biophysical properties such as rigidity or curvature